TAMERON (SODIUM AMINODIGYROPHTHALAZINEDIONE) AS A POTENT IAL COMPLEX DRUG FOR THE TREATMENT OF CORONAVIRUS INFECTION COVID-19-Reference-Cited by-同舟云学术

TAMERON (SODIUM AMINODIGYROPHTHALAZINEDIONE) AS A POTENT IAL COMPLEX DRUG FOR THE TREATMENT OF CORONAVIRUS INFECTION COVID-19

Published:2020-09-30 Issue:3 Volume:6 Page:67-75
ISSN:2587-7828
Container-title:Marine Medicine
language:
Short-container-title:Morsk. med.

Author:

Ermakov A. M.¹^ORCID,Tzar’kova E. A.²,Ermakova O. N.³^ORCID,Tzar’kov A. N.²

Affiliation:

1. Institute of Engineering Physics; Institute of Theoretical and Experimental Biophysics Russian Academy of Sciences

2. Institute of Engineering Physics

3. Institute of Theoretical and Experimental Biophysics Russian Academy of Sciences

Abstract

Coronavirus infection has caused a global pandemic with high mortality rates among the population of different countries. Drugs for non-specific immunotherapy of this infection based on sodium aminodihydrophthalazinedione (in particular, Tameron) were not considered for this purpose. It has immunomodulatory properties, and its use is not accompanied by side effects. Tameron can become a potential complex drug for the treatment of coronavirus infection COVID-19 and its use is especially important in confined spaces on ships and vessels of the military and civilian fleets.

Publisher

Baltic Medical Education Center

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Reference51 articles.

1. Omer S.B., Malani P., Del Rio C. The COVID-19 pandemic in the US: a clinical Update // JAMA. 2020. Vol. 323, No. 18. Р. 1767–1768. 10.1001/jama.2020.5788.

2. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., Chen H.D., Chen J., Luo Y., Guo H., Jiang R.D., Liu M.Q., Chen Y., Shen X.R., Wang X., Zheng X.S., Zhao K., Chen Q.J., Deng F., Liu L.L., Yan B., Zhan F.X., Wang Y.Y., Xiao G.F., Shi Z.L. A pneumonia outbreak associated with a new coronavirus of probable bat origin // Nature. 2020. Vol. 579, No. 7798. Р. 270–273. doi: 10.1038/s41586-020-2012-7.

3. Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., Yu T., Wang Y., Pan S., Zou X., Yuan S., Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir. Med. 2020. Vol. 8, No. 5. Р. 475–481. doi: 10.1016/S2213- 2600(20)30079-5.

4. Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. Version 2 // J. Pharm. Anal. 2020. Vol. 10, No. 2. Р. 102–108. doi: 10.1016/j.jpha.2020.03.001.

5. Ni W., Yang X., Yang D., Bao J., Li R., Xiao Y., Hou C., Wang H., Liu J., Yang D., Xu Y., Cao Z., Gao Z. Role of angiotensinconverting enzyme 2 (ACE2) in COVID-19 // Crit Care. 2020. Vol. 24, No. 1. Р. 422. doi: 10.1186/s13054-020-03120-0.